Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 1, 2020

Primary Completion Date

March 1, 2021

Study Completion Date

July 9, 2021

Conditions
COVID-19
Interventions
DRUG

CPI-006

Participants will receive a single dose of CPI-006 at one of four dose levels (0.3 mg/kg, 1.0 mg/kg, 3.0 mg/kg, or 5.0 mg/kg) along with standard of care.

OTHER

Standard of Care

Participants will receive standard of care treatment only.

Trial Locations (3)

10029

Icahn School of Medicine at Mount Sinai, New York

19140

Temple University Hospital, Philadelphia

92243

El Centro Regional Medical Center, El Centro

Sponsors
All Listed Sponsors
lead

Corvus Pharmaceuticals, Inc.

INDUSTRY

NCT04464395 - Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 Patients | Biotech Hunter | Biotech Hunter